

引用文献

- 1) Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295-509.
- 2) 有馬正高, 飯島昌夫, 高島宏哉, 鈴木昌樹, 春名英彦, 車田孝夫. 小児肝疾患の成因における Wilson 氏病の意義. 小児科診療 1961; 24: 425-35.
- 3) 有馬正高, 車田孝夫, 鴨下重彦. Wilson 病の遺伝学的研究,II. 遺伝型式, 地理的分布, 遺伝子頻度. 脳と神経 1963; 15: 29-35.
- 4) 有馬正高, 小宮和彦. Wilson 病, 病像の進展とその対策. 小児科診療 1965; 28: 774-90.
- 5) 佐野勇, 有馬正高. 日本における Wilson 病の遺伝的疫学的背景. 精神神経誌 1967; 69: 555-62.
- 6) Arima M, Sano I. Genetic studies of Wilson's disease in Japan. Birth Defects Original Article Series 1968; 4: 54-9.
- 7) Arima M, Takeshita K, Yoshino K, Kitahara T, Suzuki Y. Prognosis of Wilson's disease in childhood. Eur J Pediatr 1977; 126: 147-54.
- 8) 有馬正高, 西宮仁, 青木継稔, 荒島真一郎, 納光弘, 児玉浩子, 斎藤博, 春原経彦, 高柳哲也, 広瀬源二郎, 三牧孝至, 山下文雄. ウィルソン病に対する低分子金属キレート剤 塩酸トリエンチン (TJA-250) の有効性と安全性. 基礎と臨床 1992; 26: 1093-107.
- 9) 有馬正高. Wilson 病-40 年の医療の変遷. 脳と発達 1995; 27: 96-103.
- 10) Roberts EA, Schilsky ML: A practice guideline on Wilson disease. Hepatology 2003; 37: 1475-92.
- 11) Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47: 2089-111.
- 12) European Association for the study of the Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56: 671-85.
- 13) 小峰恵子, 菅谷守宏, 石垣信赴巳, 石垣朋子, 編集. ウィルソン病友の会: どう (銅) 生きる. 2009.
- 14) Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical Presentation, diagnosis and long-term outcome of Wilson disease: a cohort study. Gut 2007; 56: 115-20.
- 15) Minds 診療ガイドライン選定部会 (監). Minds 診療ガイドライン作成の手引 2007; 医学書院: 2007 年.
- 16) Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother 2003; 57: 386-98.
- 17) Kodama H, Fujisawa C, Bhadhprasit W. Inherited copper transport disorders: biochemical mechanisms, diagnosis, and treatment. Curr Drug Metab 2012; 13:

237-50.

- 18) Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. *Curr Med Chem* 2005; 12: 1161-208.
- 19) Laloiti V, Muruais G, Tsuchiya Y, Pulido D, Sandoval IV. Molecular mechanisms of copper homeostasis. *Front Biosci (Landmark Ed)* 2009; 14: 4878-903.
- 20) 厚生労働省: 平成 23 年度国民健康栄養調査結果
<http://www.mhlw.go.jp/stf/houdou/2r9852000002q1st.html>
- 21) Roberts EA, Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper. *Am J Clin Nutr* 2008; 88: 851S-4S.
- 22) Gupta A, Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. *Future Med Chem* 2009; 1: 1125-42.
- 23) Harada M. Pathogenesis and management of Wilson disease. *Hepatol Res* 2014; 44: 395-402.
- 24) Harada M, Sakisaka S, Terada K, Kimura R, Kawaguchi T, Koga H, Taniguchi E, Sasatomi K, Miura N, Suganuma T, Fujita H, Furuta K, Tanikawa K, Sugiyama T, Sata M. Role of ATP7B in biliary copper excretion in a human hepatoma cell line and normal rat hepatocytes. *Gastroenterology* 2000;118:921-8.
- 25) Harada M, Kawaguchi T, Kumemura H, Terada K, Ninomiya H, Taniguchi E, Hanada S, Baba S, Maeyama M, Koga H, Ueno T, Furuta K, Suganuma T, Sugiyama T, Sata M. The Wilson disease protein ATP7B resides in the late endosomes with Rab7 and the Niemann-Pick C1 protein. *Am J Pathol* 2005;166:499-510.
- 26) Yanagimoto C, Harada M, Kumemura H, Koga H, Kawaguchi T, Terada K, Hanada S, Taniguchi E, Koizumi Y, Koyota S, Ninomiya H, Ueno T, Sugiyama T, Sata M. Niemann-Pick C1 protein transports copper to the secretory compartment from late endosomes where ATP7B resides. *Exp Cell Res* 2009;315:119-26.
- 27) Narindrasirasak S, Kulkarni P, Deschamps P, She YM, Sarker B. Characterization and copper binding properties of human COMMD1(MURR1). *Biochemistry* 2007; 46: 3116-28.
- 28) Tao TY, Liu F, Klomp L, Wijmenga C, Gitlin JD. The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein. *J Biol Chem* 2003; 278: 41593-6.26.
- 29) van De Sluis B, Rothuizen J, Pearson PL et al. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. *Hum Mol Genet* 2002; 11: 165-173.
- 30) Rosencrantz R, Schilsky M. Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. *Semin Liver Dis* 2011; 31: 245-59.

- 31) Hayashi H, Yano M, Fujita Y, Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease. *Med Mol Morphol* 2006; 39: 121-6.
- 32) Merle U, Tuma S, Herrmann T, Muntean V, Volkmann M, Gerrke SG, Stremmel W. Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. *J Gastroenterol Hepatol* 2010; 25: 1144-50.
- 33) Saito T. An expected decrease in incidence of Wilson's disease due to decrease in consanguinity. *Jinrui Idengaku Zasshi* 1985; 30: 249-53.
- 34) Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. *Nat Genet* 1995; 9: 210-7.
- 35) Dedoussis GV, Genschel J, Sialvera TE, Bochow B, Manolaki N, Manios Y, Tsafantakis E, Schmidt H. Wilson disease: high prevalence in a mountainous area of Crete. *Ann Human Genet* 2005; 69: 268-74.
- 36) Olivarez L, Caggana M, Pass KA, Ferguson P, Brewer GJ. Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach. *Ann Hum Genet* 2001; 65: 459-63.
- 37) Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson's disease in the Republic of Ireland. *J Neurol Neurosurg Psychiatry* 1993; 56: 298-300.
- 38) 青木継稔, 原まどか, 鈴木真理子, 山口之利, 荒島真一郎. 特集 長期生存例における諸問題 Wilson 病の長期管理上の問題点. *小児科* 1992; 33: 11-21.
- 39) Mak CM, Lam CW. Diagnosis of Wilson's disease: a comprehensive review. *Crit Rev Clin Lab Sci* 2008; 45: 263-90.
- 40) Saito T. Presenting symptoms and natural history of Wilson disease. *Eur J Pediatr* 1987; 146: 261-5.
- 41) Wilson DC, Phillips MJ, Cox DW, Roberts EA. Severe hepatic Wilson's disease in preschool-aged children. *J Pediatr* 2000; 137: 719-22.
- 42) Ferenci P, Członkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W. Late-onset Wilson's disease. *Gastroenterology* 2007; 132: 1294-8.
- 43) Balistreri WF, Carey R. Wilson disease. In: Kliegman RM, Stanton BF, Schor NF, Geme JWS, Behrman R eds. *Nelson Textbook of Pediatrics* 19th ed. Elsevier Saunders, Philadelphia, PA, pp1391-2, 2011.
- 44) Milkiewicz P, Saksena S, Hubscher SG, Elias E. Wilson's disease with superimposed autoimmune features: report of two cases and review. *J Gastroenterol Hepatol* 2000; 15: 570-4.
- 45) Eisenbach C, Sieg O, Stremmel W, Encke J, Merle U. Diagnostic criteria for acute liver failure due to Wilson disease. *World J Gastroenterol* 2007; 13: 1711-4.

- 46) 虫明聡太郎, 別所一彦, 位田忍, 須磨崎亮, 乾あやの, 長田郁夫, 松井陽. 小児の劇症肝不全における劇症化の診断と予知に関する検討. 日本小児科学会雑誌 2010; 114: 64-72.
- 47) Walshe JM, Dixon AK. Dangers of non-compliance in Wilson's disease. *Lancet* 1986; 12:1:845-7.
- 48) Shaver WA, Bhatt H, Combes B. Low serum alkaline phosphatase activity in Wilson's disease. *Hepatology* 1986; 6: 859-63.
- 49) Walshe JM. The liver in Wilson's disease. In: Schiff L, Schiff ER, eds. *Diseases of the Liver*. 6th ed. Philadelphia: Lippincott; 1987. p. 1037-1050.
- 50) Czlonkowska A, Gromadzka G, Büttner J, Chabik G. Clinical features of hemolysis, elevated liver enzymes, and low platelet count syndrome in undiagnosed Wilson disease: report of two cases. *Arch Gynecol Obstet* 2010; 281: 129-34.
- 51) Czlonkowska A. A study of haemolysis in Wilson's disease. *J Neurol Sci* 1972; 16: 303-14.
- 52) 池田修一. 神経型Wilson病の臨床像と診断--精神症状および脳の画像診断を含めて(あゆみ Wilson病---最新の概念と治療戦略). *医学のあゆみ* 2006; 216: 819-21.
- 53) 長尾雅悦, 若井周治. てんかんの発症を契機にウィルソン病と診断した 1 例. *てんかんをめぐって* 2009; 28: 51-9.
- 54) Denning TR, Berrios GE. Wilson's disease. Psychiatric symptoms in 195 cases. *Arch Gen Psychiatry* 1989; 46: 1126-34.
- 55) 齋藤恒祐, 香川あすか, 柴田裕香, 得津由紀, 山田健治, 宇都宮健輔, 新開隆弘, 中村純. 精神症状が先行して発症したWilson病の1例. *精神科* 2012; 21: 463-7.
- 56) 久米井伸介, 柴田道彦, 本間雄一, 松橋亨, 日浦政明, 大西裕, 阿部慎太郎, 田原章成, 原田大. 長期にわたり統合失調症として加療されていたウィルソン病の 1 例. *肝臓* 2012; 53: 814-20.
- 57) Youn J, Kim JS, Kim HT, Lee JY, Lee PH, Ki CS, Cho JW. Characteristics of neurological Wilson's disease without Kayser-Fleischer ring. *J Neurol Sci* 2012; 323: 183-6.
- 58) Fenu M, Liggi M, Demelia E, Sorbello O, Civolani A, Demelia L. Kayser-Fleischer ring in Wilson's disease: a cohort study. *Eur J Intern Med* 2012; 23: e150-6.
- 59) Brewer GJ. Wilson's disease: a clinician's guide to recognition, diagnosis, and management. Boston: Kluwer Academic Publishers; 2001.
- 60) Brewer GJ, Askari FK. Wilson's disease: clinical management and therapy. *J Hepatol* 2005; 42: S13-21.
- 61) Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients

- from the time of diagnosis. *J Lab Clin Med* 1994; 123: 849-58.
- 62) Sternlieb I, Scheinberg IH. Prevention of Wilson's disease in asymptomatic patients. *N Engl J Med* 278:352-359, 1968.
 - 63) Giacchino R, Marazzi MG, Barabino A, Fasce L, Ciravegna B, Famularo L, Boni L, Callea F. Syndromic variability of Wilson's disease in children. Clinical study of 44 cases. *Ital J Gastroenterol Hepatol* 1997; 29: 155-61.
 - 64) Sánchez-Albisua I, Garde T, Hierro L, Camarena C, Frauca E, de la Vega A, Díaz MC, Larrauri J, Jara P. A high index of suspicion: the key to an early diagnosis of Wilson's disease in childhood. *J Pediatr Gastroenterol Nutr* 1999; 28: 186-90.
 - 65) Azizi E, Eshel G, Aladjem M. Hypercalciuria and nephrolithiasis as a presenting sign in Wilson disease. *Eur J Pediatr* 1989; 148: 548-9.
 - 66) Nakada SY, Brown MR, Rabinowitz R. Wilson's disease presenting as symptomatic urolithiasis: a case report and review of the literature. *J Urol* 1994; 152: 978-9.
 - 67) 青木継稔, 川越忠信, 藤岡芳実. 蛋白尿・血尿 Wilson 病, Wilson 病の腎合併症. *小児科* 1993; 34: 1299-304.
 - 68) 宇野拓. Wilson 病の腎障害に関する研究. *Biomed Res Trace Elem* 1998; 9: 85-94.
 - 69) Zhuang XH, Mo Y, Jiang XY, Chen SM. Analysis of renal impairment in children with Wilson's disease. *World J Pediatr* 2008; 4: 102-5.
 - 70) Golding DN, Walshe JM. Arthropathy of Wilson's disease. Study of clinical and radiological features in 32 patients. *Ann Rheum Dis* 1977; 36: 99-111.
 - 71) Chu NS, Hung TP. Geographic variations in Wilson's disease. *J Neurol Sci* 1993; 117: 1-7.
 - 72) 渡辺亘, 荒井三千雄, 鈴木堅二, 片岡洋一, 木村康德. Wilson 病に伴った膝関節軟骨石灰化症の 1 例. *整形外科* 1990; 41: 762-64.
 - 73) Pfeiffer RF. Wilson's disease. *Handb clin neurol* 2011; 100: 681-709. doi: 10.1016/B978-0-444-52014-2.00049-5.
 - 74) Kramer U, Weinberger A, Yarom R, Zoldan J, Bahar A, Godoth N. Synovial copper deposition as a possible explanation of arthropathy in Wilson's disease. *Bull Hosp J Dis* 1993; 52: 46-9.
 - 75) Carpenter TO, Carnes DL Jr, Anast CS. Hypoparathyroidism in Wilson's disease. *N Engl J Med* 1983; 309: 873-7.
 - 76) 岡田守弘, 東克彦, 榎本祥太郎, 藤井靖成, 山根広志, 辻内和司, 谷本聡, 伊藤秀一, 西岡新吾, 安井昌之, 田中智之. 副甲状腺機能低下症と無月経を伴った Wilson 病の 1 例. *日消誌* 1998; 95: 445-9.
 - 77) Krysiak R, Handzlik-Orlik G, Okopien B. Endocrine symptoms and the initial manifestation of Wilson's disease. *Yale J Biol Med* 2012; 85: 249-54.

- 78) Tarnacka B, Rodo M, Cichy S, Czlonkowska A. Procreation ability in Wilson's disease. *Acta Neurol Scand* 2000; 101: 395-8.
- 79) Klee JG. Undiagnosed Wilson's disease as cause of unexplained miscarriage. *Lancet* 1979; 2: 423.
- 80) Factor SM, Cho S, Sternlieb I, Scheinberg IH, Goldfischer S. The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases. *Virchows Arch A Pathol Anat Histol* 1982; 397: 301-11.
- 81) Weizman Z, Picard E, Barki Y, Moses S. Wilson's disease associated with pancreatitis. *J Pediatr Gastroenterol Nutr* 1988; 7: 931-3.
- 82) Chu CC, Huang CC, Chu NS. Recurrent hypokalemic muscle weakness as an initial manifestation of Wilson's disease. *Nephron* 1996; 73: 477-9.
- 83) Cairns JE, Williams HP, Walshe JM. "Sunflower cataract" in Wilson's disease. *Br Med J* 1969; 3: 95-6.
- 84) Wiebers DO, Hollenhorst RW, Goldstein NP. The ophthalmologic manifestations of Wilson's disease. *Mayo Clin Proc* 1977; 52: 409-16.
- 85) Ingster-Moati I, Bui Quoc E, Pless M, Djomby R, Orssaud C, Guichard J P, Woimant F. Ocular motility and Wilson's disease: a study on 34 patients. *J Neurol Neurosurg Psychiatry* 2007; 78: 1199-201.
- 86) Seyhan M, Erdem T, Selimoğlu MA, Ertekin V. Dermatological signs in Wilson's disease. *Pediatr Int* 2009; 51: 395-8.
- 87) Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith Jr LH, eds. *Major problems in internal medicine*, vol.23. Philadelphia, PA: WB Saunders, pp25-35, 1984.
- 88) Gromadzka G, Chabik G, Mendel T, Wierzychowska A, Rudnicka M, Czlonkowska A. Middle-aged heterozygous carriers of Wilson's disease do not present with significant phenotypic deviations related to copper metabolism. *J Genet* 2010; 89: 463-7.
- 89) Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P. Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. *J Hepatol* 1997; 27: 358-62.
- 90) Roberts EA, Cox DW. Wilson disease. *Baillieres Clin Gastroenterol* 1998; 12: 237-56.
- 91) Gaffney D, Fell GS, O'Reilly DS. ACP Best Practice No 163. Wilson's disease: acute and presymptomatic laboratory diagnosis and monitoring. *J Clin Pathol* 2000; 53: 807-12.
- 92) Brewer GJ, Dick RD, Johnson VD, Fink JK, Kluin KJ, Daniels S. Treatment of Wilson's disease with zinc XVI: Treatment during the pediatric years. *J Lab Clin*

- Med. 2001; 137: 191-8..
- 93) Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. *Hepatology* 1992; 15: 609-15.
 - 94) Tu JB, Blackwell RQ. Studies on levels of penicillamine-induced cupriuresis in heterozygotes of Wilson's disease. *Metabolism* 1967; 16: 507-13.
 - 95) Gross JB Jr, Ludwig J, Wiesner RH, McCall JT, LaRusso NF. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. *Gastroenterology* 1985; 89: 272-8.
 - 96) Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, Madl C, Maier-Dobersberger T, Herneth A, Dragosics B, Meryn S, Knoflach P, Granditsch G, Gangl A. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. *Gastroenterology* 1997; 113: 212-8.
 - 97) LaRusso NF, Summerskill WH, McCall JT. Abnormalities of chemical tests for copper metabolism in chronic active liver disease: differentiation from Wilson's disease. *Gastroenterology* 1976; 70: 653-5.
 - 98) Frommer DJ. Urinary copper excretion and hepatic copper concentrations in liver disease. *Digestion* 1981; 21: 169-78.
 - 99) Müller T, Koppikar S, Taylor RM, Carragher F, Schlenck B, Heinz-Erian P, Kronenberg F, Ferenci P, Tanner S, Siebert U, Staudinger R, Mieli-Vergani G, Dhawan A. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. *J Hepatol* 2007; 47: 270-6.
 - 100) Ferenci P, Steindl-Munda P, Vogel W, Jessner W, Gschwantler M, Stauber R, Datz C, Hackl F, Wrba F, Bauer P, Lorenz O. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. *Clin Gastroenterol Hepatol* 2005; 3:811-8.
 - 101) Song YM, Chen MD. A single determination of liver copper concentration may misdiagnose Wilson's disease. *Clin Biochem* 2000; 33:589-90.
 - 102) Johnson RE, Campbell RJ. Wilson's disease: electron microscopic, x-ray energy spectroscopic, and atomic absorption spectroscopic studies of corneal copper deposition and distribution. *Lab Invest* 1982; 46: 564-9.
 - 103) Demirkiran M, Jankovic J, Lewis RA, Cox WD: Neurologic presentation of Wilson disease without Kayser-Fleischer rings. *Neurology* 1996; 46: 1040-3.
 - 104) Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson's disease: an experience over three decades. *Gut* 2000; 46: 415-9.
 - 105) 清水教一, 鈴木真理子, 山口之利, 青木継稔, 松田一郎, 有馬正高. 全国調査からみ

た神経型・肝神経型 Wilson 病の臨床像および肝銅含量に関する検討. 脳と発達 1996; 28: 391-97.

- 106) Tauber J, Steinert RF. Pseudo-Kayser-Fleischer ring of the cornea associated with non-Wilsonian liver disease: a case report and literature review. *Cornea* 1993; 12: 74-7.
- 107) Frommer D, Morris J, Sherlock S, Abrams J, Newman S. Kayser-Fleischer-like rings in patients without Wilson's disease. *Gastroenterology* 1977; 72: 1331-5.
- 108) Kaplinsky C, Sternlieb I, Javitt N, Rotem Y. Familial cholestatic cirrhosis associated with Kayser-Fleischer rings. *Pediatrics* 1980; 65: 782-8.
- 109) Barkovich AJ. *Pediatric neuroimaging*. Lippincott Williams & Wilkins, Philadelphia, pp169-72, 2012.
- 110) 藤澤千恵、大場洋、児玉浩子. Wilson 病. *小児内科* 2007; 39 (増刊) : 520-22.
- 111) Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H. Cranial MRI in Wilson's disease. *Neuroradiology* 1990; 32: 211-4.
- 112) Roh JK, Lee TG, Wie BA, Lee SB, Park SH, Chang KH. Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease. *Neurology* 1994; 44: 1064-8.
- 113) King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, Halligan S, Hall-Craggs MA. Cranial MR imaging in Wilson's disease. *AJR Am J Roentgenol* 1996; 167: 1579-84.
- 114) van Wassenae-van Hall HN, van den Heuvel AG, Algra A, Hoogenraad TU, Mali WP. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. *Radiology* 1996; 198: 531-6.
- 115) Sinha S, Taly AB, Ravishankar S, Prashanth LK, Venugopal KS, Arunodaya GR, Vasudev MK, Swamy HS. Wilson's disease: cranial MRI observations and clinical correlation. *Neuroradiology* 2006; 48: 613-21.
- 116) Uchino A, Sawada A, Takase Y, Kudo S. Symmetrical lesions of the middle cerebellar peduncle: MR imaging and differential diagnosis. *Magn Reson Med Sci* 2004; 3: 133-40.
- 117) Aikath D, Gupta A, Chattopadhyay I, Hashmi MA, Gangopadhyay PK, Das SK, Ray K. Subcortical white matter abnormalities related to drug resistance in Wilson disease. *Neurology* 2006; 67: 878-80.
- 118) Larnaout A, Ammar N, Mourad Z, Naji S, Hentati F. Wilson's disease: appreciable improvement of sub-cortical white matter abnormalities after copper chelating treatment: five years follow-up. *Neuropediatrics* 2008; 39: 176-8.
- 119) Barbosa ER, Silveira-Moriyama L, Machado AC, Bacheschi LA, Rosemberg S, Scaff

- M. Wilson's disease with myoclonus and white matter lesions. *Parkinsonism Relat Disord* 2007; 13: 185-8.
- 120) Prashanth LK, Sinha S, Taly AB, A Mahadevan, Vasudev MK, Shankar SK. Spectrum of epilepsy in Wilson's disease with electroencephalographic, MR imaging and pathological correlates. *J Neurol Sci* 2010; 291: 44-51.
 - 121) Favrole P, Chabriat H, Guichard JP, Woimant F. Clinical correlates of cerebral water diffusion in Wilson disease. *Neurology* 2006; 66: 384-9.
 - 122) Trocello JM, Guichard JP, Leyendecker A, Pernon M, Chaine P, El Balkhi S, Poupon J, Chappuis P, Woimant F. Corpus callosum abnormalities in Wilson's disease. *J Neurol Neurosurg Psychiatry* 2011; 82: 1119-21.
 - 123) Hitoshi S, Iwata M, Yoshikawa K. Mid-brain pathology of Wilson's disease: MRI analysis of three cases. *J Neurol Neurosurg Psychiatry* 1991; 54: 624-6.
 - 124) Jacobs DA, Markowitz CE, Liebeskind DS, Galetta SL. The "double panda sign" in Wilson's disease. *Neurology* 2003; 61: 969.
 - 125) Strecker K, Schneider JP, Barthel H, Hermann W, Wegner F, Wegner A, Schwarz J, Sabri O, Zimmer C. Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?. *J Neurol* 2006; 253: 1024-9.
 - 126) Sinha S, Taly AB, Ravinshankar S, Prashanth LK, Vasudev MK. Central pontine signal changes in Wilson's disease: distinct MRI morphology and sequential changes with de-coppering therapy. *J Neuroimaging* 2007; 17: 286-91.
 - 127) Lucato LT, Otaduy MC, Barbosa ER, Machado AA, McKinney A, Bacheschi LA, Scaff M, Cerri GG, Leite CC. Proton MR spectroscopy in Wilson disease: analysis of 36 cases. *AJNR Am J Neuroradiol* 2005; 26: 1066-71.
 - 128) Tarnacka B, Szeszkowski W, Golebiowski M, Czlonkowska A. MR spectroscopy in monitoring the treatment of Wilson's disease patients. *Mov Disord* 2008; 23: 1560-6.
 - 129) Giagheddu M, Tamburini G, Piga M, Tacconi P, Giagheddu A, Serra A, Siotto P, Satta L, Demelia L, Marrosu F. Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease. *Acta Neurol Scand* 2001; 103: 71-81.
 - 130) Piga M, Murru A, Satta L, Serra A, Sias A, Loi G, Marrosu F, Demelia L. Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease. *Eur J Nucl Med Mol Imaging* 2008; 35: 716-24.
 - 131) Hermann W, Barthel H, Hesse S, Grahmann F, Kuhn HJ, Wagner A, Villmann T. Comparison of clinical types of Wilson's disease and glucose metabolism in extrapyramidal motor brain regions. *J Neurol* 2002; 249: 896-901.
 - 132) Ikegawa S, Hiraoka A, Shimizu Y, Hidaka S, Tazuya N, Ichiryu M, Nakahara H,

- Tanabe A, Tanihira T, Hasebe A, Miyamoto Y, Ninomiya T, Hirooka M, Kumagi T, Abe M, Hiasa Y, Onji M, Michitaka K. Hepatocellular carcinoma in a case of Wilson's disease treated with radiofrequency ablation therapy. *Intern Med* 2011; 50: 1433-7.
- 133) Kumagi T, Horiike N, Abe M, Kurose K, Iuchi H, Masumoto T, Joko K, Akbar SF, Michitaka K, Onji M. Small hepatocellular carcinoma associated with Wilson's disease. *Intern Med* 2005; 44:439-43.
 - 134) Mergo PJ, Ros PR, Buetow PC, Buck JL: Diffuse disease of the liver: radiologic-pathologic correlation. *Radiographics* 1994; 14:1291-307.
 - 135) 大西裕満. Wilson 病. 山下康行編、画像診断別冊 KEY BOOK シリーズ 肝胆膵の画像診断. CT・MR を中心に学研メディカル秀潤社、東京 pp252-3, 2010.
 - 136) Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. *Nat Genet* 1993; 3:7-13.
 - 137) Chelly J, Tümer Z, Tønnesen T, Petterson A, Ishikawa-Brush Y, Tommerup N, Horn N, Monaco AP. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. *Nat Genet* 1993; 3:14-9.
 - 138) Mercer JF, Livingston J, Hall B, Paynter JA, Begy C, Chandrasekharappa S, Lockhart P, Grimes A, Bhavé M, Siemieniak D, Glover TW. Isolation of a partial candidate gene for Menkes disease by positional cloning. *Nat Genet* 1993; 3:20-5.
 - 139) Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. *Nat Genet* 1993; 5:327-37.
 - 140) Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, Devoto M, Peppercorn J, Bush AI, Sternlieb I, Pirastu M, Gusella JF, Evgrafov O, Penchaszadeh GK, Honig B, Edelman IS, Soares MB, Scheinberg IH, Gilliam TC. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. *Nat Genet* 1993; 5:344-50.
 - 141) Petrukhin K, Fischer SG, Pirastu M, Tanzi RE, Chernov I, Devoto M, Brzustowicz LM, Cayanis E, Vitale E, Russo JJ, Matseoane D, Boukhgalter B, Wasco W, Figus AL, Loudianos J, Cao A, Sternlieb I, Evgrafov O, Parano E, Pavone L, Warburton D, Ott J, Penchaszadeh GK, Scheinberg IH, Gilliam TC. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. *Nat Genet* 1993; 5:338-43.
 - 142) Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver

- cDNA as a candidate gene for Wilson disease. *Biochem Biophys Res Commun* 1993; 197:271-7.
- 143) Human Gene Mutation Database (Cardiff):
<http://www.hgmd.cf.ac.uk/ac/index.php>
 - 144) Wilson's Disease Mutation Database:
<http://www.wilsondisease.med.ualberta.ca/databese.asp>
 - 145) Okada T, Shiono Y, Hayashi H, Satoh H, Sawada T, Suzuki A, Takeda Y, Yano M, Michitaka K, Onji M, Mabuchi H. Mutational analysis of ATP7B and genotype-phenotype correlation in Japanese with Wilson's disease. *Hum Mutat.* 2000; 15:454-62.
 - 146) Shimizu N, Nakazono H, Takeshita Y, Ikeda C, Fujii H, Watanabe A, Yamaguchi Y, Hemmi H, Shimatake H, Aoki T. Molecular analysis and diagnosis in Japanese patients with Wilson's disease. *Pediatr Int.* 1999; 41:409-13.
 - 147) Tatsumi Y, Hattori A, Hayashi H, Ikoma J, Kaito M, Imoto M, Wakusawa S, Yano M, Hayashi K, Katano Y, Goto H, Okada T, Kaneko S. Current state of Wilson disease patients in central Japan. *Intern Med* 2010; 49:809-15.
 - 148) Gu YH, Kodama H, Du SL, Gu QJ, Sun HJ, Ushijima H. Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease. *Clin Genet* 2003; 64:479-84.
 - 149) Wang LH, Huang YQ, Shang X, Su QX, Xiong F, Yu QY, Lin HP, Wei ZS, Hong MF, Xu XM. Mutation analysis of 73 southern Chinese Wilson's disease patients: identification of 10 novel mutations and its clinical correlation. *J Hum Genet* 2011; 56: 660-5.
 - 150) Bennett J, Hahn SH. Clinical molecular diagnosis of Wilson disease. *Semin Liver Dis* 2011; 31: 233-8.
 - 151) Alt ER, Sternlieb I, Goldfischer S. The cytopathology of metal overload. *Int Rev Exp Pathol* 1990; 31:165-88.
 - 152) Ludwig J, Moyer TP, Rakela J. The liver biopsy diagnosis of Wilson's disease. *Methods in pathology. Am J Clin Pathol.* 1994; 102:443-6.
 - 153) Langner C, Denk H. Wilson disease. *Virchows Arch* 2004; 445:111-8.
 - 154) El-Youssef M. Wilson disease. *Mayo Clin Proc* 2003; 78:1126-36.
 - 155) Johncilla M, Mitchell KA. Pathology of the liver in copper overload. *Semin Liver Dis* 2011; 31: 239-44.
 - 156) 大橋寛嗣, 川野潔, 山崎剛. NASH 類似の組織像を呈した Wilson 病の 1 例 : 銅染色の意義. *診断病理* 2004; 21: 329-32.
 - 157) Thompson R, Portman B, Roberts E. Genetic and metabolic liver disease. In: Burt

- A, Portman B, Ferrell L, editors. MacSween's Pathology of the Liver. 6th edition. London: Churchill Livingstone Elsevier; 2012. p. 157-259
- 158) Stromeyer FW, Ishak KG. Histology of the liver in Wilson's disease: a study of 34 cases. *Am J Clin Pathol* 1980; 73: 12-24.
 - 159) Gu M, Cooper JM, Butler P, Walker AP, Mistry PK, Dooley JS, Schapira AH. Oxidative-phosphorylation defects in liver of patients with Wilson's disease. *Lancet* 2000; 356: 469-74.
 - 160) Strand S, Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, Wesch H, Mariani SM, Hack V, Stremmel W, Krammer PH, Galle PR. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. *Nat Med* 1998; 4: 588-93.
 - 161) Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rübber H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Häussinger D, Gulbins E, Lang F. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. *Nat Med* 2007; 13: 164-70.
 - 162) Kinebuchi M, Matsuura A, Ohya K, Abo W, Kitazawa J. Contribution of Va24Vb11 natural killer T cells in Wilsonian hepatitis. *Clin Exp Immunol* 2005; 139: 144-51.
 - 163) Ohya K, Abo W, Tamaki H, Sugawara C, Endo T, Nomachi S, Fukushi M, Kinebuchi M, Matsuura A. Presymptomatic diagnosis of Wilson disease associated with a novel mutation of the ATP7B gene. *Eur J Pediatr* 2002; 161: 124-6.
 - 164) Lindquist RR. Studies on the pathogenesis of hepatolenticular degeneration. II. Cytochemical methods for the localization of copper. *Arch Pathol* 1969; 87: 370-9.
 - 165) Pilloni L, Lecca S, Van Eyken P, Flore C, Demelia L, Pilleri G, Nurchi AM, Farci AM, Ambu R, Callea F, Faa G. Value of histochemical stains for copper in the diagnosis of Wilson's disease. *Histopathology* 1998; 33: 28-33.
 - 166) Goldfischer S, Sternlieb I. Changes in the distribution of hepatic copper in relation to the progression of Wilson's disease (hepatolenticular degeneration). *Am J Pathol* 1968; 53: 883-901.
 - 167) 松浦晃洋, 杵渕幸. 遺伝性銅代謝疾患組織を用いた銅沈着の定量的空間的検出. *SPRING-8 メディカルバイオ・トライアルユース成果報告書* 2007; 30-2.
 - 168) Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. *Gastroenterology* 1968; 55: 354-67.
 - 169) Hanaichi T, Kidokoro R, Hayashi H, Sakamoto N. Electron probe X-ray analysis on human hepatocellular lysosomes with copper deposits: copper binding to a thiol-protein in lysosomes. *Lab Invest* 1984; 51: 592-7.

- 170) Nicastro E, Ranucci G, Vajro P, Vegnente A, Iorio R. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. *Hepatology* 2010;52:1948-56.
- 171) Iorio R, D'Ambrosi M, Mazzarella G, Varrella F, Vecchione R, Vegnente A. Early occurrence of hypertransaminasemia in a 13-month-old child with Wilson disease. *J Pediatr Gastroenterol Nutr* 2003;36:637-8.
- 172) Kalach N, Seidman EG, Morin C, Rasquin-Weber A, O'Regan S, Labergev JM, Blanchard H, et al. Acute liver failure from Wilson's disease in a five-year-old child. *Can J Gastroenterol* 1993;7:610-12.
- 173) Weiss KH: Wilson Disease. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, et al., eds. *GeneReviews(R)*. Seattle (WA), 1993.
- 174) Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, Kato M, Yanagisawa N, Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. *Ann Neurol* 1995; 37: 646-56.
- 175) Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, Hiyamuta S, Ikeda S, Shimizu N, Yanagisawa N. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. *Nat Genet* 1995; 9: 267-72.
- 176) Sakiyama Y, Narita A, Osawa S, Nanba E, Ohno K, Otsuka M: Abnormal copper metabolism in Niemann-Pick disease type C mimicking Wilson's disease. *Neurol Clin Neurosci* doi: 10.1111/ncn3.122:1-8, 2014.
- 177) Oder W, Grimm G, Kollegger H, Fernci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. *J Neurol* 1991; 238: 281-7
- 178) Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS. Wilson's disease: diagnostic errors and clinical implications. *J Neurol Neurosurg Psychiatry* 2004; 75: 907-9.
- 179) Bidaki R, Zarei M, Mirhosseini SM, Moghadami S, Hejrati M, Kohnavard M, Shariati B. Mismanagement of Wilson's disease as psychotic disorder. *Adv Biomed Res* 2012; 1:61 doi: 10.4103/2277-9175.100182.
- 180) Hoogenraad TU, Koevoet R, de Ruyter Korver EG. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). *Eur Neurol* 1979; 18(3): 205-11.
- 181) Brewer GJ, Yuzbasiyan-Gurkan V, Young AB. Treatment of Wilson's disease. *Semin Neurol* 1987; 7: 209-20.
- 182) Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. *Ann Intern Med* 1983; 99: 314-9.

- 183) Hoogenraad TU. Zinc treatment of Wilson's disease. *J Lab Clin Med* 1998; 132: 240-1.
- 184) Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. *Physiol Rev.* 65: 238-309.
- 185) Schilsky ML, Blank RR, Czaja MJ, Scheinberg IH, Stockert RJ, Sternlieb I. Hepatocellular copper toxicity and its attenuation by zinc. *J Clin Invest* 1989; 84: 1562-8.
- 186) Mizuochi T, Kimura A, Shimizu N, Nishiura H, Matsushita M, Yoshino M. Zinc monotherapy from time of diagnosis for young pediatric patients with presymptomatic Wilson disease. *J Pediatr Gastroenterol Nutr* 2011; 53: 365-7.187) Linn FH, Houwen RH, van Hattum J, van der Kleij S, van Erpecum KJ. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. *Hepatology* 2009; 50: 1442-52.
- 188) Shimizu N, Fujiwara J, Ohnishi S, Sato M, Kodama H, Kohsaka T, Inui A, Fujisawa T, Tamai H, Ida S, Itoh S, Ito M, Horiike N, Harada M, Yoshino M, Aoki T. Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. *Transl Res* 2010; 156: 350-7.
- 189) Cortese A, Zangaglia R, Lozza A, Piccolo G, Pacchetti C. Monitoring late complications of zinc treatment in Wilson's disease. *Mov Disord* 2011; 26: 2449-50.
- 190) Walshe JM. Management of penicillamine nephroopathy in Wilson's disease: a new chelating agent. *Lancet* 1969; 2: 1401-2.
- 191) Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. *Lancet* 1982; 1: 643-7.
- 192) Taylor RM, Chen Y, Dhawan A; EuroWilson Consortium. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. *Eur J Pediatr* 2009; 168: 1061-8.
- 193) Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. *Lancet* 2007; 369: 397-408.
- 194) Morita J, Yoshino M, Watari H, Yoshida I, Motohiro T, Yamashita F, Okano Y, Hashimoto T. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations. *Dev Pharmacol Ther* 1992; 19: 6-9.
- 195) Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, Merle U, Ferenci-Foerster D, Maieron A, Stauber R, Zoller H, Schmidt HH, Reuner U, Hefter H, Trocello JM, Houwen RH, Ferenci P, Stremmel W; EUROWILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. *Clin Gastroenterol Hepatol* 2013; 11: 1028-35.

- 196) Kodama H, Murata Y, Iitsuka T, Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. *Life Sci* 1997; 61: 899-907.
- 197) Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, Ferenci P, Stremmel W. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. *Gastroenterology* 2011; 140:1189-1198.
- 198) Walshe JM. Copper chelation in patients with Wilson's disease A comparison of penicillamine and triethylene tetramine dihydrochloride. *Quart J Med N.S.* 1973; XL11 167: 441-452.
- 199) Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. *Arch Neurol* 1987; 44: 490-3..
- 200) Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. *Arch Neurol* 2006; 63: 521-7.
- 201) Harada M, Miyagawa K, Honma Y, Hiura M, Shibata M, Matsushashi T, Abe S, Harada R, Tabaru A. Excess copper chelating therapy for Wilson disease induces anemia and liver dysfunction. *Intern Med* 2011; 50:1461-4.
- 202) Shiono Y, Hayashi H, Wakusawa S, Yano M. Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. *Med Electron Microsc* 2001; 34: 54-60.
- 203) Walshe JM. Wilson's disease; new oral therapy. *Lancet* 1956; 270(6906): 25-26.
- 204) Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. *N Engl J Med* 1987; 317: 209-13.
- 205) Shimono N, Ishibashi H, Ikematsu H, Kudo J, Shirahama M, Inaba S, Maeda K, Yamasaki K, Niho Y. Fulminant hepatic failure during perinatal period in a pregnant woman with Wilson's disease. *Gastroenterol Jpn* 1991; 26: 69-73.
- 206) 長嶋千佳、矢上晶子、山北高志、松永佳世子. D-ペニシラミンによる増殖性天疱瘡. *Visual Dermatolgy* 2005; 4: 386-387.
- 207) 早乙女敦子、向井秀樹、清水教一. Wilson病患者に生じた蛇行性穿孔性弾力線維症. *皮膚病診療* 2009; 31: 1395-1398.
- 208) Walshe JM, Yealland M. Chelation treatment of neurological Wilson's disease. *Q J Med* 86:197-204:1993.
- 209) Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation

- and use of prognostic index. *Gut* 1986; 27: 1377-81.
- 210) Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson's disease in children: 37-Year experience and revised King's score for liver transplantation. *Liver Transpl* 2005; 11: 441-8.
 - 211) Petrasek J, Jirsa M, Sperl J, Kozak L, Taimr P, Spicak J, Filip K, Trunecka P. Revised King's College score for liver transplantation in adult patients with Wilson's disease. *Liver Transpl* 2007; 13: 55-61.
 - 212) Lu BR, Zhang S, Narkewicz MR, Belle SH, Squires RH, Sokol RJ; Pediatric Acute Liver Failure Study Group. Evaluation of the liver injury unit scoring system to predict survival in a multinational study of pediatric acute liver failure. *J Pediatr* 2013; 162: 1010-6. e1-4. doi: 10.1016/j.jpeds.2012.11.021. Epub 2012 Dec 20.
 - 213) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班編集. 劇症肝炎の診療ガイド. 文光堂; 2010 年.
 - 214) Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, Williams R, Jalan R. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. *Liver Transpl* 2002; 8: 962-7.
 - 215) Rustom N, Bost M, Cour-Andlauer F, Lachaux A, Brunet AS, Boillot O, Bordet F, Valla F, Richard N, Javouhey E. Effect of Molecular adsorbents recirculating system treatment in children with acute liver failure caused by Wilson disease. *J Pediatr Gastroenterol Nutr* 2014; 58: 160-4.
 - 216) DuBois RS, Rodgers DO, Martineau G, Shroter G, Giles G, Lilly J, Halgrimson CG, Starzl TE, Sternlieb I, Scheinberg IH. Orthotopic liver transplantation for Wilson's disease. *Lancet* 1971; 1: 505-8.
 - 217) Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson's disease. *J Hepatol* 1995; 23: 373-81.
 - 218) 長坂博範, 小林邦彦, 高橋美智子, 大川正人, 渡辺徹. 生体部分肝移植を施行した劇症肝炎型 wilson 病の 1 症例. *肝胆膵* 1995; 30: 1023-28.
 - 219) 小松陽樹, 乾あやの, 大川貴史, 宮川芳宏, 藤沢知雄, 上本伸二, 猪股裕紀洋, 田中絃一. 生体部分肝移植にて救命し得た溶血発作を伴う劇症肝炎型の Wilson 病 (Wilsonian fulminant hepatitis) の 1 女児例. *肝臓* 1996; 37: 224-49.
 - 220) 日本肝移植研究会. 肝移植症例登録報告. *移植* 2014; 49: 261-274
 - 221) Scilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: Indications and outcome. *Hepatology* 1994; 19: 583-7.
 - 222) Asonuma K, Inomata Y, Kasahara M, Uemoto S, Egawa H, Fujita S, Kiuchi T, Hayashi M, Tanaka K. Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease. *Pediatr Transplant* 1999; 3:

201-5.

- 223) Wang XH, Cheng F, Zhang F, Li XC, Kong LB, Li GQ, Li J, Qian XF. Living-related liver transplantation for Wilson's disease. *Transpl Int* 2005; 18: 651-6.
- 224) Komatsu H, Fujisawa T, Inui A, Sogo T, Sekine I, Kodama H, Uemoto S, Tanaka K. Hepatic copper concentration in children undergoing living related liver transplantation due to Wilsonian fulminant hepatic failure. *Clin Transplant* 2002; 16: 227-32.
- 225) Schumacher G, Platz KP, Mueller AR, Neuhaus R, Steinmüller T, Bechstein WO, Becker M, Luck W, Schuelke M, Neuhaus P. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. *Clin transplant* 1997; 11: 217-24.
- 226) Medici V, Mirante VG, Fassati LR, Pompili M, Forti D, Del Gaudio M, Trevisan CP, Cillo U, Sturniolo GC, Fagiuoli S; Monotematica AISF 2000 OLT Study Group. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. *Liver Transpl* 2005; 11: 1056-63.
- 227) Catana AM, Medici V. Liver transplantation for Wilson disease. *World J Hepatol* 2012; 4: 5-10.
- 228) Akyildiz BN, Yildirim S, Kondolot M, Arslan D. Is plasma exchange effective in prevention of hepatic transplantation in fulminant Wilson disease with hepatic failure?. *J Pediatr Gastroenterol Nutr* 2011; 52: 778-80.
- 229) 日本肝移植研究会. 肝移植症例登録報告. 移植 2010; 45: 621-32.
- 230) 日本肝移植研究会. 肝移植症例登録報告. 移植 2012; 47: 416-28.
- 231) 日本肝移植研究会. 肝移植症例登録報告(第一報). 移植 2013; 48: 362-8.
- 232) Yoshitoshi EY, Takada Y, Oike F, Sakamoto S, Ogawa K, Kanazawa H, Ogura Y, Okamoto S, Haga H, Ueda M, Egawa H, Kasahara M, Tanaka K, Uemoto S. Long-term outcomes for 32 cases of Wilson's disease after living-donor liver transplantation. *Transplantation* 2009; 87: 261-7.
- 233) von Herbay A, de Groot H, Hegi U, Stremmel W, Strohmeyer G, Sies H. Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. *J Hepatol* 1994; 20: 41-6.
- 234) Shimizu N, Yamaguchi Y, Aoki T. Treatment and management of Wilson's disease. *Pediatr Int* 1999; 41: 419-22.
- 235) 厚生労働省：「日本人の食事摂取基準（2015年版）策定検討会」報告書
<http://www.mhlw.go.jp/stf/shingi/0000041824.html>
- 236) 厚生労働省：平成 24 年度国民健康栄養調査結果
<http://www.mhlw.go.jp/stf/houdou/0000032074.html>

- 237) 山崎大治. 低銅食について (資料 食品中の銅含有量及び常用量銅含有量) 会報 Will No.15、ウイルソン病友の会事務局発行 2003 年発行; pp7-11.
- 238) Brewer GJ. Overview of management for the clinician: What's important and what's not. Brewer GJ ed. Wilson's disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Kluwer Acad Pub, Boston 2001; pp69-78.
- 239) Marcellini M, Di Ciommo V, Callea F, Devito R, Comparcola D, Sartorelli MR, Carelli G, Nobili V. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med 2005; 145: 139-43.
- 240) Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142: 385-90.
- 241) Dasty M, Procházková D, Pokorný A, Zdrážil L. Copper and zinc in the serum, urine, and hair of patients with Wilson's disease treated with penicillamine and zinc. Biol Trace Elem Res 2010; 133: 265-9. doi; 10. 1007/s12011-009-8438-2. Epub 2009 Jun 27.
- 242) Lange J. Long-term treatment of Wilson's disease with D-penicillamine. Report on 20 cases. Dtsch Med Wochenschr 1967; 92: 1657-62.
- 243) Goldstein NP, Tauxe WN, McCall JT, Randall RV, Gross JB. Wilson's disease (hepatolenticular degeneration). Treatment with penicillamine and changes in hepatic trapping of radioactive copper. Arch Neurol 1971; 24: 391-400.
- 244) Berry WR, Aronson AE, Darley FL, Goldstein NP. Effects of penicillamine therapy and low-copper diet on dysarthria in Wilson's disease (hepatolenticular degeneration). Mayo Clin Proc 1974; 49: 405-8.
- 245) Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77: 137-46.
- 246) Medici V, Trevisan CP, D'Incá R, Barollo M, Zancan L, Fagioli S, Martines D, Irato P, Sturniolo GC. Diagnosis and management of Wilson's disease: results of a single center experience. J Clin Gastroenterol 2006; 40: 936-41.
- 247) 清水教一, 藤原順子, 山口之利, 大西眞, 佐藤真理, 児玉浩子, 香坂隆夫, 藤澤知雄, 乾あやの, 玉井浩, 位田忍, 伊藤進, 伊藤道徳, 堀池典生, 原田大, 佐田通夫, 芳野信, 青木継稔. 本邦における Wilson 病に対する酢酸亜鉛製剤(NPC-02)の有効性と安全性に関する検討. 日本先天代謝異常学会誌 2008; 24: 71-80.
- 248) 清水教一. Wilson 病に対する亜鉛治療の実際. 亜鉛栄養治療 2011; 2: 30-4.
- 249) Walshe JM, Munro NA. Zinc-induced deterioration in Wilson's disease aborted by

- treatment with penicillamine, dimercaprol, and a novel zero copper diet. *Arch Neurol* 1995; 52: 10-1.
- 250) Walshe JM. The management of Wilson's disease with triethylenetetramine 2HCl (Trient 2HCl). *Prog Clin Biol Res* 1979; 34: 271-80.
 - 251) Medalia A, Scheinberg IH. Psychopathology in patients with Wilson's disease. *Am J Psychiatry* 1989; 146: 662-4.
 - 252) Krim E, Barroso B. Psychiatric disorders treated with clozapine in a patient with Wilson's disease. *J Neuropsychiatry Clin Neurosci* 2001; 13: 531-1.
 - 253) Kulaksizoglu IB, Polat A. Quetiapine for mania with Wilson's disease. *Psychosomatics* 2003; 44: 438-9.
 - 254) Chroni E, Lekka NP, Tsibri E, Economou A, Paschalis C. Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease. *J Neuropsychiatry Clin Neurosci* 2001; 13: 531-2.
 - 255) Kato O, Ota N. Risperidone and lithium for personality and behavioral changes with Wilson's Disease. *Prim Care Companion J Clin Psychiatry* 2009; 11: 368.
 - 256) Loganathan S, Nayak R, Sinha S, Taly AB, Math S, Vaghese M. Treating mania in Wilson's disease with lithium. *J Neuropsychiatry Clin Neurosci* 2008; 20: 487-489.
 - 257) Rich AM, Lajoie TM. Wilson's disease -- Treatment of psychiatric manifestations in pregnancy. *Psychosomatics* 2012; 53: 175-7. doi: 10.1016/j. psym. 2012. 01. 002.
 - 258) Davanzo R, Copertino M, De Cunto A, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature. *Breastfeed Med* 2011; 6: 89-98.
 - 259) Bem RS, Muzzillo DA, Deguti MM, Barbosa ER, Werneck LC, Teive HA. Wilson's disease in southern Brazil: a 40-year follow-up study. *Clinics* 2011; 66: 411-6.
 - 260) El-Karakasy H, Fahmy M, El-Raziky MS, El-Hawary M, El-Sayed R, El-Koofy N, El-Mougy F, El-Hennawy A, El-Shabrawi M. A clinical study of Wilson's disease: the experience of a single Egyptian paediatric hepatology unit. *Arab J Gastroenterol* 2011; 12: 125-30.
 - 261) Wong RJ, Gish R, Schilsky M, Frenette C. A clinical assessment of Wilson disease in patients with concurrent liver disease. *J Clin Gastroenterol* 2011 45: 267-73.
 - 262) 清水教一、水口浩一、井上美沙子、小川絢子、青木継稔. 全国調査からみた Wilson 病治療に関する検討. *日本先天代謝異常学会雑誌* 2009; 25: 170.
 - 263) 清水教一、井上美沙子、小川絢子、青木継稔. 全国調査からみた神経型・肝神経 Wilson 病の治療に関する検討. *脳と発達* 44 2012; S217. (学会抄録)
 - 264) 清水教一. シンポジウム: 新しい治療法の適応とガイドライン Wilson 病. *日本先天代謝異常学会雑誌* 2011; 27: 25-30.
 - 265) 青木継稔. Wilson 病研究の進展—わが国における Wilson 病患者の自然歴の解明と分

- 子病態解析に関する研究一. 日本先天代謝異常学会雑誌 2004; 20: 18-26.
- 266) 青木継稔. Wilson 病の全国追跡調査成績. 小児内科 1991; 23: 1893-8.
- 267) 青木継稔. 遺伝性銅代謝異常症の臨床とその分子病態. Biomedical Research on Trace Elements 2004; 15: 307-15.
- 268) Sokol RJ. Copper metabolism and copper storage disorders. 4th ed. New York: Cambridge University Press 2014; 752.
- 269) Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr, Fontana RJ, Lee WM, Schilsky ML; Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008; 48: 1167-74.
- 270) Ohya Y, Okajima H, Honda M, Hayashida S, Suda H, Matsumoto S, Lee KJ, Yamamoto H, Takeichi H, Asonuma K, Endo F, Inomata Y. Re-evaluation of the indications for liver transplantation in Wilson's disease based on the outcomes of patients referred to a transplant center. Pediatr Transplant 2013;17:369-373.
- 271) Markiewicz-Kijewska M, Szymczak M, Ismail H, Prokurat S, Teisseire J, Socha P, Jankowska I, Chyżyńska A, Kaliciński P, Migdał M. Liver transplantation for fulminant Wilson's disease in children. Ann Transplant 2008;13:28-31.
- 272) Lee WM, PR.T. S, A.M. L. AASLD Position Paper: The Management of Acute Liver Failure: Update 2011. Hepatology 2011..
- 273) Jhang JS, Schilsky ML, Lefkowitz JH, Schwartz J. Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease. J Clin Apher 2007; 22: 10-4.
- 274) Aydinli M, Harmanci O, Ersoy O, Iskit AT, Ozcebe O, Abbasoglu O, Bayraktar Y. Two unusual cases with Wilson's disease: hepatoma and fulminant hepatitis treated with plasma exchange. J Natl Med Assoc 2006; 98: 1989-91.
- 275) Nagata Y, Uto H, Hasuike S, Ido A, Hayashi K, Eto T, Hamakawa T, Tanaka K, Tsubouchi H. Bridging use of plasma exchange and continuous hemodiafiltration before living donor liver transplantation in fulminant Wilson's disease. Intern Med 2003; 42: 967-70.
- 276) Chiu A, Tsoi NS, Fan ST. Use of the molecular adsorbents recirculating system as a treatment for acute decompensated Wilson disease. Liver Transpl 2008; 14: 1512-6.
- 277) Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Löht M, Liebe S, Schareck W, Hopt UT, Schmidt R. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif

Organs 1999; 23: 319-30.

- 278) Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballauff A, Wallot M, Borchers T, Vester U, Grasemann C, Hauffa B, Hoyer PF, Gerken G, Voit T. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. *J Pediatr Gastroenterol Nutr* 2005; 40: 54-9.
- 279) Aagaard NK, Thomsen KL, Holland-Fischer P, Jørgensen SP, Ott P. A 15-year-old girl with severe hemolytic Wilson's crisis recovered without transplantation after extracorporeal circulation with the Prometheus system. *Blood Purif* 2009; 28: 102-7.
- 280) Morgan SM, Zantek ND. Therapeutic plasma exchange for fulminant hepatic failure secondary to Wilson's disease. *J Clin Apher* 2012; 27: 282-286.
- 281) Arnon R, Annunziato R, Schilsky M, Miloh T, Willis A, Sturdevant M, Sakworawich A, Suchy F, Kerkar N. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. *Clin Transplant* 2011; 25: E52-60.
- 282) Scheinberg IH, Sternlieb I. Pregnancy in penicillamine-treated patients with Wilson's disease. *N Engl J Med* 1975; 293: 1300-2.
- 283) Sternlieb I. Wilson's disease and pregnancy. *Hepatology* 2000; 31: 531-2.
- 284) Brewer GJ, Johnson VD, Dick RD, Hedera P, Fink JK, Kluin K. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. *Hepatology* 2000; 31: 364-70.
- 285) Messner U, Günter HH, Niesert S. Wilson disease and pregnancy. Review of the literature and case report. *Z Geburtshilfe Neonatol* 1998; 202: 77-9.
- 286) 泉陽一, 小川英伸, 児玉浩子, 菊池陽. Wilson 病患者母親は母乳育児が可能か? 日本小児科学会雑誌 2012; 116: 455.
- 287) Brewer GJ, Yuzbasiyan-Gurkan V, Lee DY, Appelman H. Treatment of Wilson's disease with zinc. VI. initial treatment studies. *J Lab Clin Med* 1989; 114: 633-8.
- 288) Stremmel W, Meyerrose KW, Niederau C, Heftner H, Kreuzpaintner G, Strohmeyer G. Wilson Disease: Clinical presentation, treatment, and survival. *Ann Intern Med* 1991; 115: 720-6.
- 289) Santos Silva EE, Sarles J, Buts JP, Sokal EM. Successful medical treatment of severely decompensated Wilson disease. *J Pediatr.* 1996; 128: 285-7.
- 290) Iwadate H, Ohira H, Suzuki T, Abe K, Yokokawa J, Takiguchi J, Rai T, Orikasa H, Obara K, Kasukawa R, Sato Y. Hepatocellular carcinoma associated with Wilson's disease. *Intern Med* 2004; 43: 1042-5.
- 291) Kumagi T, Horiike N, Michitaka K, Hasebe A, Kawai K, Tokumoto Y, Nakanishi S,

- Furukawa S, Hiasa Y, Matsui H, Kurose K, Matsuura B, Onji M. Recent clinical features of Wilson's disease with hepatic presentation. *J Gastroenterol* 2004; 39: 1165-9.
- 292) Kodama H, Fujisawa C. Copper metabolism and inherited copper transport disorders: molecular mechanisms, screening, and treatment. *Metallomics* 2009; 1: 42-52.
- 293) 青木継稔、清水教一、山口之利. Wilson 病の長期予後と問題点. *小児内科* 2001; 33: 921-8.
- 294) Pellecchia MT, Criscuolo C, Longo K, Campanella G, Filla A, Barone P. Clinical presentation and treatment of Wilson's disease: a single-centre experience. *Eur Neurol* 2003; 50: 48-52.
- 295) Prashanth LK, Taly AB, Sinha S, Ravishankar S, Arunodaya GR, Vasudev MK, Swamy HS. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease. *QJM* 2005; 98: 557-63.
- 296) Burke JF, Dayalu P, Nan B, Askari F, Brewer GJ, Lorincz MT. Prognostic significance of neurologic examination findings in Wilson disease. *Parkinsonism Relat Disord* 2011; 17: 551-6.
- 297) Burton K, Farrell K, Li D, Calne DB. Lesions of the putamen and dystonia: CT and magnetic resonance imaging. *Neurology* 1984; 34: 962-5.
- 298) Hölscher S, Leinweber B, Hefter H, Reuner U, Günther P, Weiss KH, Oertel WH, Möller JC. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. *Eur Neurol* 2010; 64: 83-7.
- 299) 井上美佐子, 小川絢子, 清水教一, 関根孝司, 菅原由美, 栗山進一, 青木継稔. Wilson 病における予後に関連する因子に関する検討. *日本先天代謝異常学会雑誌* 2010; 26: 133.
- 300) Svetel M, Pekmezovic T, Petrovic I, Tomic A, Kresojevic N, Jesic R, Kazic S, Raicevic R, Stefanovic D, Delibasic N, Zivanovic M, Kostic VS. Long-term outcome in Serbian patients with Wilson disease. *Europ J Neurol* 2009; 16: 852-7.
- 301) Reynolds HV, Talekar CR, Bellapart J, Leggett BA, Boots RJ. Copper removal strategies for Wilson's disease crisis in the ICU. *Anaesth Intensive Care* 2014; 42: 253-7.
- 302) Fischer RT, Soltys KA, Squires RH Jr, Jaffe R, Mazariegos GV, Shneider BL. Prognostic scoring indices in Wilson disease: a case series and cautionary tale. *J Pediatr Gastroenterol Nutr* 2011; 52: 466-9.

- 303) Eghtesad B, Nezakatgoo N, Geraci LC, Jabbour N, Irish WD, Marsh W, Fung JJ, Rakela J. Liver transplantation for Wilson's disease: a single-center experience. *Liver Transpl Surg* 1999; 5: 467-74.
- 304) Guillaud O, Dumortier J, Sobesky R, Debray D, Wolf P, Vanlemmens C, Durand F, Calmus Y, Duvoux C, Dharancy S, Kamar N, Boudjema K, Bernard PH, Pageaux GP, Salamé E, Gugenheim J, Lachaux A, Habes D, Radenne S, Hardwigsen J, Chazouillères O, Trocello JM, Woimant F, Ichaï P, Branchereau O, Castaing D, Jacquemin E, Samuel D, Duclos-Vallée JC. Long term results of liver transplantation for Wilson's disease: experience in France. *J Hepatol* 2014; 60: 579-89.
- 305) Weiss KH, Schäfer M, Gotthardt DN, Angerer A, Mogler C, Schirmacher P, Schemmer P, Stremmel W, Sauer P. Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. *Clin Transplant* 2013; 27:914-22.
- 306) Narumi S, Umehara M, Toyoki Y, Ishido K, Kudo D, Kimura N, Kobayashi T, Sugai M, Hakamada K. Liver transplantation for Wilson's disease in pediatric patients: decision making and timing. *Transplant Proc* 2012; 44: 478-80.
- 307) 日本肝移植学会. 肝移植症例登録報告. 移植 2011; 46: 524-36
- 308) Cheng F, Li GQ, Zhang F, Li XC, Sun BC, Kong LB, Pu LY, Wang K, Qian XF, You W, You W, Wang XH. Outcomes of living-related liver transplantation for Wilson's disease: a single-center experience in China. *Transplantation* 2009; 87:751-7.
- 309) Berman DH, Leventhal RI, Gavalier JS, Cadoff EM, Van Thiel DH. Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. *Gastroenterology* 1991;100:1129-34.
- 310) Collins KL, Roberts EA, Adeli K, Bohn D, Harvey EA. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. *Pediatr Nephrol* 2008; 23:1013-6.
- 311) 朝比奈靖浩, 坂本直哉, 神山俊典, 田沢潤一, 西村正信, 佐藤千史, 丸茂文昭. 治療中止後急性肝不全と溶血性貧血を呈して死亡した Wilson 病の 1 例. *肝臓* 1992; 33: 649-53.
- 312) 稲毛康司. 思春期における健康問題 小児から成人への移行期小児医療の特性. *小児内科* 2007; 39: 1292-6.
- 313) 楠隆. 「薬に関する素朴な疑問」処方されている薬は、実際にはどのくらいが服用されているのでしょうか。アドヒアランスをあげるコツがあれば教えてください. *小児内科* 2008; 40: 243-5.
- 314) Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and

medication adherence in HIV-positive drug users. *AIDS Patient Care and STDs* 2004; 18: 385-93.

- 315) Irvine L, Crombie IK, Alder EM, Neville RG, Clark RA. What predicts poor collection of medication among children with asthma? A case-control study. *Eur Respir J* 2002; 20, 1464-9.
- 316) 木下博子. 服薬アドヒアランスを上げるための工夫・薬を飲めない子への対応（特集 エキスパートが教える研修医のための薬の使いかた）. *小児科診療* 2011; 74: 729-32.